Arcutis Biotherapeutics (ARQT) Short Interest Ratio & Short Volume $14.86 +1.29 (+9.51%) (As of 12/17/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Arcutis Biotherapeutics Short Interest DataArcutis Biotherapeutics (ARQT) has a short interest of 23.53 million shares. This marks a -5.96% decrease in short interest from the previous month. The short interest ratio (days to cover) is 11.8, indicating that it would take 11.8 days of the average trading volume of 3.13 million shares to cover all short positions.Current Short Interest23,530,000 sharesPrevious Short Interest25,020,000 sharesChange Vs. Previous Month-5.96%Dollar Volume Sold Short$306.83 millionShort Interest Ratio11.8 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares117,045,000 sharesPercentage of Shares Shorted20.10%Today's Trading Volume3,866,227 sharesAverage Trading Volume3,132,033 sharesToday's Volume Vs. Average123% Short Selling Arcutis Biotherapeutics? Sign up to receive the latest short interest report for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartARQT Short Interest Over TimeARQT Days to Cover Over TimeARQT Percentage of Float Shorted Over Time Ad Brownstone ResearchDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. Arcutis Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/202423,530,000 shares $306.83 million -6.0%N/A11.8 $13.04 11/15/202425,020,000 shares $231.69 million -9.9%N/A12.8 $9.26 10/31/202427,760,000 shares $230.69 million -1.1%N/A13.1 $8.31 10/15/202428,060,000 shares $262.36 million +3.4%N/A13.7 $9.35 9/30/202427,130,000 shares $252.31 million +9.1%N/A12.7 $9.30 9/15/202424,860,000 shares $265.01 million +0.7%N/A10.5 $10.66 Get the Latest News and Ratings for ARQT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/202424,680,000 shares $268.52 million +3.7%N/A9.9 $10.88 8/15/202423,800,000 shares $202.30 million +8.4%N/A9 $8.50 7/31/202421,950,000 shares $221.04 million -3.1%N/A7.8 $10.07 7/15/202422,660,000 shares $244.05 million +6.2%N/A8 $10.77 6/30/202421,340,000 shares $198.46 million -18.0%N/A7 $9.30 6/15/202426,020,000 shares $224.55 million +5.6%N/A8.7 $8.63 5/31/202424,640,000 shares $205.99 million +11.1%N/A7.7 $8.36 5/15/202422,170,000 shares $204.85 million +2.2%N/A6 $9.24 4/30/202421,690,000 shares $180.46 million +10.3%N/A5.7 $8.32 4/15/202419,660,000 shares $198.37 million +2.1%N/A4.3 $10.09 3/31/202419,260,000 shares $190.87 million +28.5%N/A4 $9.91 3/15/202414,990,000 shares $159.79 million -5.0%N/A2.8 $10.66 2/29/202415,780,000 shares $162.22 million -6.9%N/A2.6 $10.28 2/15/202416,940,000 shares $135.01 million +1.0%N/A2.9 $7.97 1/31/202416,780,000 shares $98.50 million -19.4%N/A3.1 $5.87 1/15/202420,830,000 shares $75.82 million +3.2%N/A4.1 $3.64 12/31/202320,180,000 shares $65.18 million +3.7%N/A4.2 $3.23 12/15/202319,460,000 shares $47.48 million -6.9%N/A4.8 $2.44 11/30/202320,900,000 shares $38.46 million +19.4%N/A8.2 $1.84 11/15/202317,510,000 shares $36.42 million +2.6%N/A8 $2.08 10/31/202317,070,000 shares $38.41 million +21.4%N/A8.5 $2.25 10/15/202314,060,000 shares $54.55 million +8.3%N/A8.7 $3.88 9/30/202312,980,000 shares $68.92 million -2.3%29.0%12.1 $5.31 9/15/202313,280,000 shares $90.44 million +6.4%29.7%13.1 $6.81 8/31/202312,480,000 shares $106.58 million -19.2%27.9%11.3 $8.54 8/15/202315,450,000 shares $130.86 million +1.6%34.5%12.8 $8.47 7/31/202315,210,000 shares $165.94 million +3.1%33.9%12.3 $10.91 7/15/202314,760,000 shares $139.33 million +0.2%32.8%11.9 $9.44 6/30/202314,730,000 shares $140.38 million +12.5%32.8%11.3 $9.53 6/15/202313,090,000 shares $133.78 million +0.4%29.1%10 $10.22 5/31/202313,040,000 shares $97.93 million -13.1%29.1%10.3 $7.51 5/15/202315,010,000 shares $154.60 million -2.5%33.7%13.1 $10.30 4/30/202315,390,000 shares $213.00 million +0.3%35.2%15.6 $13.84 4/15/202315,350,000 shares $213.21 million +1.5%35.1%15.5 $13.89How to piss off your liberal friends… and profit from it (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now 3/31/202315,120,000 shares $166.32 million +10.0%34.5%15.4 $11.00 3/15/202313,750,000 shares $152.76 million +11.1%31.4%14.9 $11.11 2/28/202312,380,000 shares $200.31 million +4.2%28.2%15 $16.18 2/15/202311,880,000 shares $203.62 million +10.1%27.2%15 $17.14 1/31/202310,790,000 shares $178.79 million +0.5%25.0%13 $16.57 1/15/202310,740,000 shares $151.65 million +0.9%24.9%13.1 $14.12 12/30/202210,650,000 shares $157.62 million +6.8%24.7%13.9 $14.80 12/15/20229,970,000 shares $164.41 million +5.1%23.1%12.7 $16.49 11/30/20229,490,000 shares $163.51 million +17.9%22.0%12.6 $17.23 11/15/20228,050,000 shares $156.49 million +0.1%18.7%10.8 $19.44 10/31/20228,040,000 shares $142.15 million +17.4%19.2%12.1 $17.68 10/15/20226,850,000 shares $127.68 million +14.4%16.4%9.1 $18.64 9/30/20225,990,000 shares $114.47 million +15.2%14.3%8.6 $19.11 9/15/20225,200,000 shares $97.19 million +1.6%12.5%7.7 $18.69 8/31/20225,120,000 shares $137.98 million -1.7%12.4%8.4 $26.95 8/15/20225,210,000 shares $128.79 million +13.8%12.9%9 $24.72 7/31/20224,580,000 shares $111.11 million +16.8%12.6%8.2 $24.26 7/15/20223,920,000 shares $94.86 million +12.3%12.6%9.5 $24.20 6/30/20223,490,000 shares $74.37 million +5.8%11.3%8.6 $21.31 6/15/20223,300,000 shares $67.82 million +6.8%10.5%8.6 $20.55 5/31/20223,090,000 shares $64.52 million +6.2%9.8%8.8 $20.88 5/15/20222,910,000 shares $52.18 million -1.4%9.5%9.8 $17.93 4/30/20222,950,000 shares $59.56 million +3.2%9.6%10.5 $20.19 4/15/20222,860,000 shares $60.15 million -15.4%9.5%10.3 $21.03 3/31/20223,380,000 shares $65.10 million -9.1%12.1%12.5 $19.26 3/15/20223,720,000 shares $59.45 million +15.9%13.3%15.9 $15.98 2/28/20223,210,000 shares $57.14 million +3.2%11.4%15.8 $17.80 2/15/20223,110,000 shares $51.32 million +6.9%11.1%14.4 $16.50 1/31/20222,910,000 shares $43.97 million +26.0%10.6%14.5 $15.11 1/15/20222,310,000 shares $40.22 million +9.0%8.4%12.4 $17.41 12/31/20212,120,000 shares $43.97 million +7.1%7.7%12.7 $20.74 12/15/20211,980,000 shares $31.68 million No Change7.2%11.7 $16.00 11/30/20211,980,000 shares $32.81 million -1.0%7.2%12.1 $16.57 11/15/20212,000,000 shares $40.50 million +0.5%7.3%13.3 $20.25 10/29/20211,990,000 shares $42.15 million +1.0%7.2%14 $21.18 10/15/20211,970,000 shares $43.89 million -0.5%7.2%12.7 $22.28 9/30/20211,980,000 shares $47.30 million -4.4%7.2%12.1 $23.89 9/15/20212,070,000 shares $45.08 million -5.5%7.5%11.6 $21.78 8/31/20212,190,000 shares $46.36 million -4.0%8.0%12.6 $21.17 8/13/20212,280,000 shares $46.69 million -1.3%8.3%13.2 $20.48 7/30/20212,310,000 shares $53.89 million +2.2%8.5%11.3 $23.33 7/15/20212,260,000 shares $56.23 million No Change6.8%9.6 $24.88 6/30/20212,260,000 shares $61.68 million -0.9%6.8%9.5 $27.29 6/15/20212,280,000 shares $65.00 million -1.3%6.9%10.4 $28.51 5/28/20212,310,000 shares $60.87 million -0.9%6.9%10.4 $26.35 5/14/20212,330,000 shares $59.53 million +17.7%7.0%9.9 $25.55 4/30/20211,980,000 shares $60.49 million -0.5%6.4%8.4 $30.55 4/15/20211,990,000 shares $55.90 million +7.0%6.5%7.7 $28.09 3/31/20211,860,000 shares $50.07 million +19.2%6.0%7.2 $26.92 3/15/20211,560,000 shares $50.78 million +9.9%5.1%5.6 $32.55How to piss off your liberal friends… and profit from it (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now 2/26/20211,420,000 shares $48.62 million +0.7%4.6%5.1 $34.24 2/12/20211,410,000 shares $49.08 million -6.6%4.7%5.2 $34.81 1/29/20211,510,000 shares $39.35 million -8.5%5.4%5.8 $26.06 1/15/20211,650,000 shares $47.01 million No Change6.6%8.4 $28.49 ARQT Short Interest - Frequently Asked Questions What is Arcutis Biotherapeutics' current short interest? Short interest is the volume of Arcutis Biotherapeutics shares that have been sold short but have not yet been covered or closed out. As of November 30th, traders have sold 23,530,000 shares of ARQT short. Learn More on Arcutis Biotherapeutics' current short interest. What is a good short interest ratio for Arcutis Biotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ARQT shares currently have a short interest ratio of 12.0. Learn More on Arcutis Biotherapeutics's short interest ratio. Is Arcutis Biotherapeutics' short interest increasing or decreasing? Arcutis Biotherapeutics saw a drop in short interest in November. As of November 30th, there was short interest totaling 23,530,000 shares, a drop of 6.0% from the previous total of 25,020,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Arcutis Biotherapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Arcutis Biotherapeutics: Legend Biotech Co. (13.04%), Nuvalent, Inc. (12.26%), Blueprint Medicines Co. (6.60%), Elanco Animal Health Incorporated (3.15%), Cytokinetics, Incorporated (12.35%), TG Therapeutics, Inc. (20.71%), Viking Therapeutics, Inc. (16.22%), BridgeBio Pharma, Inc. (11.52%), Crinetics Pharmaceuticals, Inc. (6.48%), Krystal Biotech, Inc. (12.69%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Arcutis Biotherapeutics stock? Short selling ARQT is an investing strategy that aims to generate trading profit from Arcutis Biotherapeutics as its price is falling. ARQT shares are trading up $1.29 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Arcutis Biotherapeutics? A short squeeze for Arcutis Biotherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ARQT, which in turn drives the price of the stock up even further. How often is Arcutis Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ARQT, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies Legend Biotech Short Squeeze Nuvalent Short Squeeze Blueprint Medicines Short Squeeze Elanco Animal Health Short Squeeze Cytokinetics Short Squeeze TG Therapeutics Short Squeeze Viking Therapeutics Short Squeeze BridgeBio Pharma Short Squeeze Crinetics Pharmaceuticals Short Squeeze Krystal Biotech Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ARQT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARQT Stock Alerts